Physician profile
James S May
NPI 1255361879
$11,129.76
in general payments reported to CMS, 2019-2025
35 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,127 · 2020: $1,793 · 2021: $1,809 · 2022: $2,334 · 2023: $1,339 · 2024: $1,190 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,047.44 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,868.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,345.22 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,113.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,098.70 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $828.22 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $719.92 | 2021-2025 | |
| Amarin Pharma, INC. | $673.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.83 | 2019-2024 | Jardiance |
| Allergan, INC. | $261.69 | 2019 | |
| Merck Sharp & Dohme LLC | $259.11 | 2019-2022 | |
| Pfizer INC. | $248.98 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $245.57 | 2019-2023 | Livalo |
| Abbvie INC. | $233.79 | 2021-2022 | |
| Astellas Pharma US INC | $232.53 | 2019-2023 | Veozah |
| Abbott Laboratories | $201.04 | 2021-2025 | Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $168.31 | 2021 | |
| Esperion Therapeutics, INC. | $164.78 | 2020-2022 | |
| Daiichi Sankyo INC. | $142.71 | 2022-2023 | Injectafer |
| Zimmer Biomet Holdings, INC. | $92.57 | 2020 | |
| Novartis Pharmaceuticals Corporation | $85.40 | 2019-2024 | |
| Inspire Medical Systems, INC. | $75.27 | 2025 | Inspire |
| Mannkind Corporation | $59.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $57.38 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $50.43 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $27.79 | 2020-2021 | |
| Dexcom, INC. | $24.38 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $21.81 | 2023 | Ekosonic |
| Shield Therapeutics INC | $21.55 | 2022 | |
| Cardiva Medical, INC. | $21.04 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Avanir Pharmaceuticals, INC. | $17.13 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.10 | 2023 | Nuzyra |
| Sumitomo Pharma America, INC. | $15.93 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $15.09 | 2024 | Voquezna |
| Athena Bioscience, LLC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.